RxSight holders back directors, pay and auditor

RxSight, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026.

Rhea-AI Filing Summary

RxSight, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Of 41,396,609 common shares outstanding as of April 21, 2026, 33,299,192 were represented, about 80.4% of shares entitled to vote.

Stockholders re-elected three Class II directors — William J. Link, Robert Warner, and Shweta Singh Maniar — to serve until the 2029 annual meeting and until their successors are elected and qualified.

They also approved, on an advisory basis, executive compensation, with 21,236,615 votes for and 2,742,189 against, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 33,062,585 votes for and 92,653 against.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares outstanding: 41,396,609 shares Shares represented: 33,299,192 shares Say-on-pay votes for: 21,236,615 votes +4 more

7 metrics

Shares outstanding 41,396,609 shares Common stock outstanding as of April 21, 2026

Shares represented 33,299,192 shares Shares present or by proxy at 2026 annual meeting (~80.4%)

Say-on-pay votes for 21,236,615 votes Advisory approval of executive compensation

Say-on-pay votes against 2,742,189 votes Advisory approval of executive compensation

Auditor ratification votes for 33,062,585 votes Ratification of Ernst & Young LLP for 2026 fiscal year

Auditor ratification votes against 92,653 votes Ratification of Ernst & Young LLP for 2026 fiscal year

William J. Link votes for 21,086,793 votes Re-election as Class II director

Key Terms

broker non-votes, advisory vote, independent registered public accounting firm, emerging growth company

4 terms

broker non-votes financial

"Broker Non-Votes | 9,277,003"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

advisory vote financial

"Advisory Vote on Executive Compensation. The stockholders approved, on an advisory basis"

An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.

independent registered public accounting firm financial

"Appointment of Ernst & Young LLP as our independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What key items did RxSight (RXST) stockholders vote on at the 2026 annual meeting?

Stockholders voted on three main items: re-election of three Class II directors, an advisory approval of executive compensation, and ratification of Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year.

How many RxSight (RXST) shares were represented at the 2026 annual meeting?

A total of 33,299,192 RxSight common shares were represented at the meeting, out of 41,396,609 shares outstanding as of April 21, 2026, meaning about 80.4% of eligible shares were present or represented by proxy.

Were RxSight (RXST) directors re-elected at the 2026 annual meeting?

Yes. Stockholders re-elected three Class II directors—William J. Link, Robert Warner, and Shweta Singh Maniar—to serve until the 2029 annual meeting and until their successors are duly elected and qualified, based on the reported voting results.

Did RxSight (RXST) stockholders approve executive compensation in 2026?

Yes. In the advisory vote on executive compensation, 21,236,615 votes were cast in favor, 2,742,189 against, and 43,385 abstained, with 9,277,003 broker non-votes, indicating stockholder approval of the named executive officers’ compensation.

Which audit firm did RxSight (RXST) stockholders ratify for the 2026 fiscal year?

Stockholders ratified Ernst & Young LLP as RxSight’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 33,062,585 votes for, 92,653 against, and 143,954 abstentions, and no broker non-votes reported for this item.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:30 PM Learn about SEC filing dates

false000111148500011114852026-06-162026-06-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40690	94-3268801
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California				92656
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 521-7830

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		RXST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

We held our 2026 Annual Meeting of Stockholders (“Annual Meeting”) on June 16, 2026. Of the 41,396,609 shares of our common stock outstanding as of April 21, 2026, 33,299,192 shares of common stock were represented, either by attending the virtual annual meeting or by proxy, constituting, of the shares entitled to vote, approximately 80.4% of the outstanding shares of common stock. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below.

1.Election of Three Class II Directors. The following nominees were re-elected by the holders of our common stock to serve as our Class II directors to hold office until our 2029 annual meeting of stockholders and until their successors have been duly elected and qualified:

Nominee		For				Against				Abstain				Broker Non-Votes
William J. Link			21,086,793				—				2,935,396				9,277,003
Robert Warner			15,667,180				—				8,355,009				9,277,003
Shweta Singh Maniar			13,850,389				—				10,171,800				9,277,003

2.Advisory Vote on Executive Compensation. The stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement based on the following results of voting:

For				Against				Abstain				Broker Non-Votes
	21,236,615				2,742,189				43,385				9,277,003

3.Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:

For				Against				Abstain				Broker Non-Votes
	33,062,585				92,653				143,954				—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			RxSight, Inc.
Date:	June 16, 2026	By:	/s/ Mark Wilterding
			Name: Mark Wilterding Title: Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB